Latanoprost/Trabodenoson

N/A

Report date: 2022/09/02 20:00:31

Base Information

Drug NameLatanoprost/Trabodenoson
Drug Alias NameLatanoprost and Trabodenoson拉坦前列素/TrabodenosonTrabodenoson/LatanoprostINO-8875/trabodenosonPJ 875/trabodenoson +[6] 
ClassificationSmall molecules
Mechanisms of ActionAdenosine A1 receptor agonistsProstanoid FP receptor agonists
TargetsProstanoid FP receptorAdenosine A1 receptor
Therapy Area/IndicationsGlaucoma, Open-AngleOcular Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes TrabodenosonLatanoprost
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRocket Pharmaceuticals IncInotek Pharmaceuticals Corporation
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInotek Pharmaceuticals Corporation
Active IndicationsN/A
Inactive IndicationsGlaucoma, Open-AngleOcular Hypertension

Other Information

ATC CodeN/A
Related LinksN/A